680 results about "Colitis" patented technology

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention relates to an oral probiotic-mediated drug delivery system as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing polydopamine nano coating bacteria from probiotics and dopamine; a process of preparing drug-loaded polydopamine nanoparticles from dopamine and a functional drug; and a process of preparing a drug delivery system from the polydopamine nano-coated bacteria and the drug-loaded polydopamine nanoparticles, the drug delivery system prepared by the method is applied to preparation of drugs for preventing or treating tumors, colitis, diarrhea, constipation, diabetes mellitus and obesity. The preparation method disclosed by the invention has the advantages of simple preparation, mildness and stable performance, the prepared drug delivery system adopts a polydopamine single bacterium coating method to encapsulate the probiotics, and the drug-loaded nanoparticles are loaded on the surface of the probiotics, so that the effects of efficient drug delivery and micro-ecological regulation functions are achieved, and a better treatment effect is achieved.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

The invention discloses an ulcerative colitis image classification method based on a multi-scale attention fusion network, belongs to the technical field of image information mining and classification, and combines a staged feature extraction backbone network, a multi-scale attention fusion module (SCHL) and a classification module. The ulcerative colitis lesion image classification method has the advantages that significant advantages are shown in ulcerative colitis lesion image automatic classification tasks, an OfficientNet backbone network has staged feature extraction capacity, multi-level information from shallow texture to deep semantics in lesion images can be effectively captured, an SCHL module performs modeling by fusing channel attention, space attention and level high-frequency information, and the ulcerative colitis lesion image classification efficiency is improved. The model is guided to focus on a key lesion area, background interference is inhibited, feature discrimination is enhanced, the recognition ability of the model to a fine-grained lesion form and the generalization ability of the model to a complex clinical image are remarkably improved, and higher accuracy and robustness are achieved in refined classification of ulcerative colitis.

The invention discloses anti-inflammatory polypeptide nanoparticles and a preparation method thereof, and belongs to the technical field of bioactive peptides. The anti-inflammatory polypeptide nano-particles are nano-particles obtained by coating polypeptide with an anti-inflammatory effect with chitosan and sodium tripolyphosphate, the polypeptide with the anti-inflammatory effect contains bioactive peptides of which the amino acid sequences are YAADQ, FPYTT and YVTYA. The phycocyanin anti-inflammatory peptide is natural in source, the performance of the phycocyanin anti-inflammatory peptide can be remarkably improved through the nanometer embedding technology, and compared with traditional drugs, the phycocyanin anti-inflammatory peptide has lower toxic and side effects and potential cost advantages. The polypeptide nanoparticles prepared by the invention can effectively prevent the phycocyanin anti-inflammatory peptide from being degraded in the digestive tract, have a remarkable treatment effect on mice with ulcerative colitis, and have an important application prospect in preparation of ulcerative colitis prevention and treatment products.

The invention relates to the technical field of microorganisms, in particular to an anti-inflammatory compound probiotic and application thereof.Lactobacillus rhamnosus LGD-0817, lactobacillus rhamnosus LDL-1708 and lactobacillus plantarum LEP-1208 serve as basic dominant bacteria and then are compounded with multiple bacteria such as lactobacillus casei, lactobacillus delbrueckii and lactobacillus paracasei, the multiple bacteria can be matched and promoted mutually, and the anti-inflammatory compound probiotic has the anti-inflammatory effect. The traditional Chinese medicines jointly play a significant role in improving ulcerative colitis; the anti-inflammatory compound probiotics are used for traditional Chinese medicine fermentation, and the obtained traditional Chinese medicine fermentation composition can regulate intestinal flora, enhance the barrier function of the intestinal tract, inhibit release of proinflammatory factors, improve the shortening of the colon length of a mouse with colitis, inhibit the levels of proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha, competitively inhibit colonization of pathogenic bacteria and improve the colonization of colitis. The method shows a good comprehensive intervention effect in a DSS-induced mouse ulcerative colitis model, and has clinical practical value.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The invention relates to a quercetin nanocrystal and a preparation method and application of a quercetin nanocrystal preparation, and the preparation method of the quercetin nanocrystal comprises the following steps: step 1, mixing a quercetin absolute ethyl alcohol solution and a geniposide aqueous solution, and centrifuging to obtain a precipitate; and 2, washing the precipitate with distilled water, discarding the supernatant, adding the precipitate into water, dispersing to obtain a quercetin-geniposide suspension, and freeze-drying to obtain the quercetin nanocrystal. The geniposide is used as a carrier to prepare the quercetin nanocrystal, the geniposide is used for regulating and controlling the morphology and size of the quercetin nanocrystal to enable the quercetin nanocrystal to play a synergistic effect, and the effect of the quercetin on treating ulcerative colitis is greatly improved.

The invention provides a bacteriostatic agent aiming at yersinia enterocolitica and application, the bacteriostatic agent comprises a compound solution of lipoic acid and protocatechualdehyde, and when the lipoic acid and the protocatechualdehyde act synergistically, the minimum inhibitory concentrations to the yersinia enterocolitica are 0.625 mg / mL and 0.3125 mg / mL respectively. The yersinia enterocolitica biofilm is inhibited and / or removed through the lipoic acid and protocatechuic aldehyde compound liquid, and the problem that drugs for treating the yersinia enterocolitica infection are prone to drug resistance is solved.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

A use of oleanolic acid-28-O-β-D-glucopyranoside in the preparation of an anti-colitis drug is provided. The oleanolic acid-28-O-β-D-glucopyranoside has significant anti-ulcerative-colitis activity compared with parent nucleus oleanolic acid and other analogues, and has equivalent efficacy compared with Mesalazine, a first-line drug for the clinical treatment of inflammatory bowel disease, and can also avoid salicylic acid anaphylaxis possibly caused by Mesalazine western medicine treatment, thereby achieving a good application prospect.

Disclosed herein is a method of treating an individual afflicted with moderate to severe ulcerative colitis, the method comprising: administering a local inhibitor of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-alpha) to an intestine of the individual.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3Kδ pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea / colitis, respiratory infections, and hematologic toxicities.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention relates to a microbial single-cell gelation encapsulation method based on aloe gel and application, the method realizes single-cell gelation encapsulation through electrostatic interaction of sterile aloe gel and intestinal anaerobic bacteria (such as Agathobacter rectasis), and the method comprises the specific steps of aloe gel preparation, bacterial suspension culture and oscillation mixing to form a stable structure. The preparation method has the advantages that the acid resistance and biocompatibility of the natural aloe gel are utilized to replace a traditional synthetic material, so that the gastrointestinal tolerance of thalli is improved; meanwhile, the synergistic effect of aloe active ingredients (such as aloe-emodin) and intestinal bacterial metabolites (butyric acid) is combined, so that the anti-inflammatory and intestinal steady-state regulation and control effects are enhanced. Experiments show that the survival rate of the encapsulated bacteria in simulated gastric juice within 4 hours is larger than or equal to 90%, the intestinal colonization rate is effectively increased compared with naked bacteria, the inflammatory factor level of a colitis model mouse can be remarkably reduced, and a safe and efficient new strategy is provided for micro-ecological treatment of inflammatory bowel diseases.

The invention discloses lotus leaf homogeneous polysaccharide LLP3-1 as well as a separation and purification method and application thereof, and belongs to the technical field of plant polysaccharide. The lotus leaf homogeneous polysaccharide LLP3-1 is composed of rhamnose, arabinose, galactose and galacturonic acid, the molar percentage of monosaccharide is 21.95: 25.33: 21.10: 31.62, the lotus leaf homogeneous polysaccharide LLP3-1 is acidic pectin polysaccharide with RG-I as a main structural domain and with part of side chains, the main chain is mainly composed of galacturonic acid and rhamnose, and the side chains are mainly composed of arabinose and galactose. The lotus leaf homogeneous polysaccharide LLP3-1 has the beneficial effects that the lotus leaf homogeneous polysaccharide LLP3-1 can obviously improve the symptoms of ulcerative colitis; the compound can be widely applied to preparation of medicines for treating ulcerative colitis, medicines for inhibiting proinflammatory factor secretion, antioxidation medicines, medicines for improving intestinal barrier integrity and functions, medicines for promoting short-chain fatty acid generation and medicines for improving intestinal flora disorder of ulcerative colitis.

The present invention relates to pharmaceutical compounds of Formula (I):as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.